Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 32 | 2024 | 22371 | 2.090 |
Why?
|
Lung Neoplasms | 26 | 2024 | 13586 | 1.710 |
Why?
|
Minority Groups | 10 | 2024 | 1216 | 1.630 |
Why?
|
Sexual Dysfunction, Physiological | 4 | 2024 | 364 | 1.340 |
Why?
|
Medical Oncology | 16 | 2024 | 2346 | 1.330 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 17 | 2024 | 5432 | 1.180 |
Why?
|
Hematology | 3 | 2023 | 243 | 1.130 |
Why?
|
Physicians, Women | 3 | 2023 | 517 | 1.050 |
Why?
|
Immunotherapy | 8 | 2024 | 4755 | 0.880 |
Why?
|
Physicians | 6 | 2024 | 4598 | 0.870 |
Why?
|
Medical Tourism | 1 | 2023 | 51 | 0.840 |
Why?
|
Sexuality | 1 | 2024 | 179 | 0.840 |
Why?
|
Vaginal Diseases | 1 | 2023 | 103 | 0.820 |
Why?
|
Education, Medical | 2 | 2025 | 1742 | 0.800 |
Why?
|
Weather | 1 | 2023 | 234 | 0.790 |
Why?
|
Thoracic Neoplasms | 1 | 2024 | 269 | 0.770 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2024 | 260 | 0.760 |
Why?
|
Electronics | 1 | 2022 | 317 | 0.720 |
Why?
|
Mentors | 2 | 2023 | 671 | 0.710 |
Why?
|
Medicine | 2 | 2024 | 945 | 0.700 |
Why?
|
Emigrants and Immigrants | 2 | 2023 | 550 | 0.680 |
Why?
|
Peer Group | 1 | 2024 | 700 | 0.620 |
Why?
|
Humans | 119 | 2025 | 768166 | 0.600 |
Why?
|
Breast Neoplasms, Male | 2 | 2020 | 213 | 0.590 |
Why?
|
Early Detection of Cancer | 5 | 2024 | 3239 | 0.550 |
Why?
|
Climate Change | 1 | 2023 | 509 | 0.540 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 8054 | 0.540 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5367 | 0.530 |
Why?
|
Research Personnel | 1 | 2020 | 589 | 0.510 |
Why?
|
Hedgehog Proteins | 1 | 2020 | 771 | 0.500 |
Why?
|
Faculty, Medical | 1 | 2023 | 1226 | 0.470 |
Why?
|
Social Support | 1 | 2024 | 2193 | 0.460 |
Why?
|
Healthcare Disparities | 9 | 2024 | 3415 | 0.450 |
Why?
|
Career Choice | 3 | 2023 | 769 | 0.450 |
Why?
|
Latin America | 4 | 2023 | 416 | 0.440 |
Why?
|
Registries | 3 | 2024 | 8375 | 0.430 |
Why?
|
Patient Compliance | 1 | 2023 | 2697 | 0.420 |
Why?
|
Congresses as Topic | 2 | 2023 | 812 | 0.410 |
Why?
|
Female | 51 | 2025 | 397192 | 0.400 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2022 | 1188 | 0.400 |
Why?
|
Students, Medical | 1 | 2025 | 1964 | 0.370 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2062 | 0.370 |
Why?
|
Papillomavirus Infections | 1 | 2023 | 1640 | 0.370 |
Why?
|
Women's Health | 1 | 2020 | 2082 | 0.360 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2043 | 0.360 |
Why?
|
Names | 1 | 2020 | 54 | 0.360 |
Why?
|
Biomedical Research | 2 | 2020 | 3463 | 0.340 |
Why?
|
Curriculum | 1 | 2023 | 3782 | 0.330 |
Why?
|
Sex Characteristics | 1 | 2020 | 2650 | 0.330 |
Why?
|
Sex Factors | 7 | 2023 | 10632 | 0.320 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1757 | 0.320 |
Why?
|
Breast Neoplasms | 7 | 2023 | 21206 | 0.310 |
Why?
|
Videoconferencing | 1 | 2021 | 209 | 0.310 |
Why?
|
Patient Selection | 3 | 2023 | 4260 | 0.300 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2019 | 186 | 0.300 |
Why?
|
Quality of Life | 2 | 2024 | 13490 | 0.300 |
Why?
|
United States | 23 | 2025 | 73039 | 0.290 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 4413 | 0.290 |
Why?
|
Awards and Prizes | 1 | 2021 | 365 | 0.270 |
Why?
|
Teaching Rounds | 1 | 2021 | 282 | 0.270 |
Why?
|
South America | 2 | 2024 | 180 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 11878 | 0.260 |
Why?
|
Societies, Medical | 5 | 2023 | 3968 | 0.260 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 343 | 0.250 |
Why?
|
Gynecology | 1 | 2021 | 534 | 0.250 |
Why?
|
Esophageal Fistula | 1 | 2015 | 60 | 0.240 |
Why?
|
Gastroenterology | 1 | 2021 | 593 | 0.240 |
Why?
|
Bronchial Fistula | 1 | 2015 | 83 | 0.240 |
Why?
|
Health Status Disparities | 2 | 2024 | 1885 | 0.240 |
Why?
|
Cultural Diversity | 1 | 2018 | 373 | 0.240 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26379 | 0.230 |
Why?
|
Radiation Oncology | 1 | 2020 | 572 | 0.230 |
Why?
|
Male | 32 | 2024 | 364719 | 0.230 |
Why?
|
Obstetrics | 1 | 2021 | 681 | 0.230 |
Why?
|
Acetonitriles | 1 | 2024 | 55 | 0.230 |
Why?
|
Social Environment | 1 | 2019 | 1012 | 0.230 |
Why?
|
Breast | 2 | 2020 | 1976 | 0.220 |
Why?
|
Smoking | 1 | 2020 | 9092 | 0.220 |
Why?
|
Health Services Accessibility | 6 | 2024 | 5520 | 0.220 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2022 | 4058 | 0.220 |
Why?
|
Committee Membership | 1 | 2023 | 18 | 0.210 |
Why?
|
Pandemics | 5 | 2022 | 8748 | 0.210 |
Why?
|
Educational Status | 1 | 2020 | 2515 | 0.210 |
Why?
|
Self-Help Groups | 1 | 2024 | 194 | 0.210 |
Why?
|
Patient Participation | 1 | 2022 | 1447 | 0.210 |
Why?
|
Caribbean Region | 1 | 2023 | 193 | 0.210 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11244 | 0.210 |
Why?
|
Workplace | 1 | 2019 | 873 | 0.210 |
Why?
|
Radiosurgery | 1 | 2022 | 1330 | 0.200 |
Why?
|
Burnout, Professional | 1 | 2021 | 711 | 0.200 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5446 | 0.200 |
Why?
|
Disabled Persons | 1 | 2021 | 1210 | 0.190 |
Why?
|
Demography | 2 | 2024 | 1641 | 0.190 |
Why?
|
Aged | 18 | 2024 | 171504 | 0.190 |
Why?
|
Access to Information | 1 | 2024 | 317 | 0.180 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 928 | 0.180 |
Why?
|
Attitude of Health Personnel | 2 | 2022 | 3929 | 0.180 |
Why?
|
Terminal Care | 1 | 2022 | 1770 | 0.180 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 7454 | 0.180 |
Why?
|
Comorbidity | 2 | 2021 | 10590 | 0.180 |
Why?
|
Brazil | 1 | 2024 | 1250 | 0.180 |
Why?
|
Pyridines | 2 | 2024 | 2894 | 0.170 |
Why?
|
Prostatic Neoplasms | 3 | 2023 | 11101 | 0.170 |
Why?
|
Sexual Behavior | 2 | 2023 | 2197 | 0.160 |
Why?
|
Time Factors | 1 | 2021 | 40218 | 0.160 |
Why?
|
Multiple Myeloma | 2 | 2018 | 5196 | 0.160 |
Why?
|
Public Health | 2 | 2023 | 2679 | 0.160 |
Why?
|
Communication | 2 | 2023 | 3905 | 0.150 |
Why?
|
Family | 2 | 2024 | 3209 | 0.150 |
Why?
|
Palliative Care | 2 | 2023 | 3643 | 0.150 |
Why?
|
Retrospective Studies | 11 | 2024 | 81762 | 0.150 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 899 | 0.150 |
Why?
|
Middle Aged | 16 | 2024 | 223492 | 0.140 |
Why?
|
Exercise Therapy | 1 | 2024 | 939 | 0.140 |
Why?
|
RNA, Neoplasm | 1 | 2020 | 749 | 0.140 |
Why?
|
Social Justice | 1 | 2022 | 486 | 0.140 |
Why?
|
Travel | 1 | 2023 | 805 | 0.140 |
Why?
|
Internship and Residency | 2 | 2023 | 5953 | 0.140 |
Why?
|
Fatigue | 1 | 2024 | 1557 | 0.140 |
Why?
|
Anilides | 1 | 2020 | 413 | 0.140 |
Why?
|
Parental Leave | 2 | 2023 | 92 | 0.140 |
Why?
|
Prognosis | 5 | 2023 | 30010 | 0.140 |
Why?
|
Pyrimidines | 2 | 2024 | 3048 | 0.140 |
Why?
|
Drug Tolerance | 1 | 2018 | 365 | 0.130 |
Why?
|
Pregnancy | 6 | 2024 | 30256 | 0.130 |
Why?
|
Job Satisfaction | 2 | 2021 | 548 | 0.130 |
Why?
|
Treatment Refusal | 1 | 2019 | 433 | 0.130 |
Why?
|
Melanoma | 2 | 2019 | 5706 | 0.130 |
Why?
|
Fellowships and Scholarships | 3 | 2023 | 1135 | 0.130 |
Why?
|
Adult | 12 | 2025 | 223646 | 0.130 |
Why?
|
Sex Distribution | 1 | 2020 | 2278 | 0.120 |
Why?
|
Self Report | 2 | 2024 | 3773 | 0.120 |
Why?
|
Heart Diseases | 1 | 2018 | 2819 | 0.120 |
Why?
|
Patient Care | 2 | 2022 | 629 | 0.120 |
Why?
|
Vascular Surgical Procedures | 1 | 2023 | 1506 | 0.120 |
Why?
|
Cost of Illness | 1 | 2024 | 1951 | 0.120 |
Why?
|
Forecasting | 1 | 2023 | 2945 | 0.120 |
Why?
|
International Cooperation | 2 | 2020 | 1436 | 0.110 |
Why?
|
Urban Population | 1 | 2022 | 2046 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2024 | 5315 | 0.110 |
Why?
|
Qualitative Research | 1 | 2025 | 3140 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2554 | 0.110 |
Why?
|
Sirolimus | 1 | 2020 | 1540 | 0.110 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.100 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.100 |
Why?
|
Fertility | 2 | 2024 | 771 | 0.100 |
Why?
|
Education, Medical, Graduate | 3 | 2023 | 2420 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3886 | 0.100 |
Why?
|
Spain | 1 | 2023 | 485 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2302 | 0.100 |
Why?
|
Lactams | 1 | 2022 | 159 | 0.090 |
Why?
|
Organophosphorus Compounds | 1 | 2022 | 211 | 0.090 |
Why?
|
Pilot Projects | 1 | 2024 | 8741 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9419 | 0.090 |
Why?
|
Rural Population | 1 | 2022 | 2325 | 0.090 |
Why?
|
Advance Directives | 1 | 2022 | 249 | 0.090 |
Why?
|
Insurance Coverage | 1 | 2022 | 1946 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6316 | 0.090 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4912 | 0.080 |
Why?
|
Venezuela | 1 | 2019 | 73 | 0.080 |
Why?
|
Lung | 2 | 2023 | 10099 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13676 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6793 | 0.080 |
Why?
|
Aminopyridines | 1 | 2022 | 580 | 0.080 |
Why?
|
Etoposide | 1 | 2019 | 639 | 0.070 |
Why?
|
Exercise | 1 | 2024 | 5955 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2235 | 0.070 |
Why?
|
Policy | 1 | 2021 | 513 | 0.070 |
Why?
|
Population Surveillance | 1 | 2018 | 2596 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4206 | 0.070 |
Why?
|
Indians, North American | 1 | 2020 | 354 | 0.070 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3837 | 0.070 |
Why?
|
Prevalence | 2 | 2023 | 15869 | 0.070 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 1001 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2018 | 428 | 0.070 |
Why?
|
Decision Making | 1 | 2019 | 3953 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7852 | 0.060 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 581 | 0.060 |
Why?
|
Culture | 1 | 2019 | 622 | 0.060 |
Why?
|
Paclitaxel | 1 | 2022 | 1733 | 0.060 |
Why?
|
Risk Assessment | 2 | 2021 | 24315 | 0.060 |
Why?
|
Research | 2 | 2023 | 1979 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2019 | 1836 | 0.060 |
Why?
|
Philippines | 1 | 2024 | 95 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2020 | 3436 | 0.060 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15662 | 0.060 |
Why?
|
Cuba | 1 | 2024 | 48 | 0.060 |
Why?
|
Mastectomy, Segmental | 1 | 2019 | 974 | 0.060 |
Why?
|
Central America | 1 | 2024 | 69 | 0.060 |
Why?
|
Dominican Republic | 1 | 2024 | 78 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 829 | 0.060 |
Why?
|
Cisplatin | 1 | 2019 | 1660 | 0.050 |
Why?
|
BRCA2 Protein | 1 | 2018 | 802 | 0.050 |
Why?
|
Interviews as Topic | 1 | 2020 | 2741 | 0.050 |
Why?
|
Hospitalization | 1 | 2023 | 10840 | 0.050 |
Why?
|
Puerto Rico | 1 | 2024 | 380 | 0.050 |
Why?
|
Pneumonectomy | 1 | 2019 | 1156 | 0.050 |
Why?
|
Pyrazoles | 1 | 2022 | 2028 | 0.050 |
Why?
|
Medically Underserved Area | 1 | 2024 | 268 | 0.050 |
Why?
|
BRCA1 Protein | 1 | 2018 | 1155 | 0.050 |
Why?
|
Leadership | 1 | 2021 | 1397 | 0.050 |
Why?
|
Mexico | 1 | 2024 | 769 | 0.050 |
Why?
|
Bronchi | 1 | 2015 | 850 | 0.050 |
Why?
|
Mastectomy | 1 | 2019 | 1861 | 0.050 |
Why?
|
Menopause | 1 | 2019 | 1656 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3556 | 0.040 |
Why?
|
Censuses | 1 | 2022 | 198 | 0.040 |
Why?
|
Prospective Studies | 2 | 2024 | 54926 | 0.040 |
Why?
|
Thalidomide | 1 | 2016 | 886 | 0.040 |
Why?
|
Oligopeptides | 1 | 2016 | 1194 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2227 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 89169 | 0.040 |
Why?
|
Masks | 1 | 2022 | 214 | 0.040 |
Why?
|
Advisory Committees | 1 | 2024 | 797 | 0.040 |
Why?
|
Data Collection | 1 | 2018 | 3327 | 0.040 |
Why?
|
Bronchoscopy | 1 | 2015 | 914 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74944 | 0.040 |
Why?
|
Developing Countries | 1 | 2022 | 2910 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2022 | 427 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6526 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6847 | 0.040 |
Why?
|
Mammography | 1 | 2020 | 2433 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2603 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5863 | 0.040 |
Why?
|
Dexamethasone | 1 | 2016 | 1965 | 0.040 |
Why?
|
Vulnerable Populations | 1 | 2024 | 718 | 0.040 |
Why?
|
Death | 1 | 2023 | 683 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2022 | 3800 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2830 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1338 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8542 | 0.040 |
Why?
|
Signal Transduction | 1 | 2020 | 23645 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2022 | 4055 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2023 | 59629 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2022 | 840 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10399 | 0.030 |
Why?
|
Health Facilities | 1 | 2022 | 578 | 0.030 |
Why?
|
Survival Analysis | 1 | 2019 | 10101 | 0.030 |
Why?
|
Mass Screening | 1 | 2022 | 5458 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1767 | 0.030 |
Why?
|
Logistic Models | 1 | 2020 | 13290 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5703 | 0.030 |
Why?
|
Health Personnel | 1 | 2019 | 3385 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2016 | 2100 | 0.030 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2015 | 1483 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2020 | 65371 | 0.030 |
Why?
|
Recurrence | 1 | 2016 | 8509 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8647 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5341 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6669 | 0.030 |
Why?
|
Cause of Death | 1 | 2022 | 3721 | 0.020 |
Why?
|
Health Policy | 1 | 2023 | 2698 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2726 | 0.020 |
Why?
|
Delirium | 1 | 2001 | 1697 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9669 | 0.020 |
Why?
|
Critical Care | 1 | 2001 | 2715 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20760 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2517 | 0.020 |
Why?
|
Anxiety | 1 | 2001 | 4672 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6809 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15948 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36743 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 60066 | 0.010 |
Why?
|
Depression | 1 | 2001 | 8230 | 0.010 |
Why?
|
Colombia | 1 | 2001 | 287 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39348 | 0.010 |
Why?
|
Psychotropic Drugs | 1 | 2001 | 881 | 0.010 |
Why?
|
Drug Utilization | 1 | 2001 | 1189 | 0.010 |
Why?
|
Child | 1 | 2023 | 80917 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41754 | 0.010 |
Why?
|
Alcoholism | 1 | 2001 | 1980 | 0.010 |
Why?
|
Concepts
(271)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(36)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_